Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Seel
Search This Board:
Last Post: 1/27/2015 9:44:13 AM - Followers: 118 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Idera Announces Leadership Appointments 01/26/2015 04:30:00 PM
IDRA News: Current Report Filing (8-k) 01/12/2015 08:31:44 AM
IDRA News: Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference 01/09/2015 01:00:00 PM
IDRA News: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia 12/30/2014 08:00:00 AM
IDRA News: Current Report Filing (8-k) 12/17/2014 08:12:20 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1524   IBB, IDRA and many pharmas have already shrugged Citrati 01/27/15 09:44:12 AM
#1523   Grabbed a few thousand under $4.50. Looks THEPK5 01/26/15 02:52:33 PM
#1522   Had got out before it went into the THEPK5 01/15/15 03:10:25 PM
#1521   I hope so binks 01/14/15 09:47:59 PM
#1520   I hope so binks 01/14/15 09:47:58 PM
#1519   :-) gr8 one binchey 01/14/15 03:55:23 PM
#1518   from your mouth to "gut's" ears. (just a Drano 01/14/15 03:53:19 PM
#1517   IDRA is trading really well. My god feeling binchey 01/14/15 03:25:11 PM
#1516   Executives should be able to get at least binchey 01/14/15 02:46:58 PM
#1515   IDRA continues to ride the 10 day comfortably. Citrati 01/14/15 02:38:44 PM
#1514   8k released this morning includes the new Investor CHM_760 01/12/15 08:46:59 AM
#1513   Nope :*( jimmybob 01/09/15 06:48:11 AM
#1512   I think $5. is in the bag. Your TheHound 01/09/15 01:06:06 AM
#1511   Are you in this jb? binks 01/08/15 09:49:54 PM
#1510   Hopefully we can get a 5$+ close to binks 01/08/15 09:48:56 PM
#1509   Just when you think she's in for a TheHound 01/08/15 04:51:20 PM
#1508   I know! Was pleasantly surprised by todays action. Seel 01/05/15 07:27:44 PM
#1507   Congrats longs....still getting mojo. IDRA Citrati 01/05/15 10:13:46 AM
#1506   & double digits would be a lock that time... binchey 01/03/15 03:23:32 PM
#1505   On top of all this, IDRA would be binchey 01/02/15 01:56:03 PM
#1504   DLBCL should also get "orphan" status in April, binchey 01/02/15 01:51:57 PM
#1503   Congrats. 100% move on todays 12% gain. Citrati 01/02/15 01:49:25 PM
#1502   It's my target but I have a Jan Stocktillyoudrop 01/02/15 01:36:38 PM
#1501   Is that the end of your march? Citrati 01/02/15 01:29:09 PM
#1500   OOOppps. Meant double since Nov 24. Still Citrati 01/02/15 01:07:49 PM
#1499   Nice break to the upside from a bull Citrati 01/02/15 12:45:46 PM
#1498   $IDRA looking good here, on the march to $5. Stocktillyoudrop 01/02/15 11:53:36 AM
#1497   ClayTrader - IDRA chart - posted yesterday - Seel 12/30/14 12:22:03 PM
#1496   Finally.:) Seel 12/30/14 11:29:39 AM
#1495   Looks like new eyes here...Congrats to all the Citrati 12/30/14 09:56:13 AM
#1494   Added to my watch list. JRT 12/30/14 08:30:00 AM
#1493   Very nice KingDMC 12/30/14 08:14:30 AM
#1492   Idera reports third dose cohort in ongoing WM jimmybob 12/30/14 08:09:54 AM
#1491   Idera confirms FDA grants orphan drug designation for IMO-8400 jimmybob 12/30/14 08:09:39 AM
#1490   Plus this is not blind a trial, IDRA binchey 12/30/14 06:51:21 AM
#1489   Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants PennyMoocher69 12/29/14 06:19:13 PM
#1488   * * $IDRA Video Chart 12-29-14 * * ClayTrader 12/29/14 05:03:56 PM
#1487   Golden cross today, great to see ! (50 day binchey 12/26/14 11:52:35 AM
#1486   http://seekingalpha.com/article/2773545-idera-pharmaceuticals-going-into-2015 leakdog 12/22/14 06:32:56 PM
#1485   $IDRA DD Notes ~ http://www.ddnotesmaker.com/IDRA stocktrademan 12/18/14 10:51:40 AM
#1484   A good market day for IDRA to close Citrati 12/18/14 09:28:15 AM
#1483   Piper Jaffray picks for 2015 • 10:38 AM CHM_760 12/17/14 10:43:21 AM
#1482   Idera named Top Small Cap Pick for 2015 CHM_760 12/17/14 09:30:04 AM
#1481   Interesting premarket action. Citrati 12/17/14 09:07:58 AM
#1480   Key bounce to watch for tomorrow if it DITRLI 12/15/14 09:49:36 PM
#1479   Congrats on your gains. I am guessing Citrati 12/15/14 07:53:11 PM
#1478   I sold out here about a week ago, Randolph Duke 12/15/14 06:27:48 PM
#1477   This was my comment on another board. Citrati 12/15/14 04:56:13 PM
#1476   Obviously following overall market, but anybody buying on THEPK5 12/15/14 02:56:29 PM
#1475   There is our 10ema test. A nice bounce, Citrati 12/12/14 10:13:11 AM
PostSubject